Even though data from the ABCSG-18 study revealed that the combinatorial use of Denosumab with standard neoadjuvant therapy (aromatase inhibitor) significantly improved the disease-free survival (DFS) of postmenopausal women with hormone receptor-positive early breast cancer [38], another clinical trial, the D-CARE study, demonstrated that adjuvant Dmab did not improve either bone metastasis-free survival or disease-free survival in women with early breast cancer [39], while bone-related outcomes were improved [40]. Here, CYP19A1 is linked to breast carcinoma.